To further explore this subject, we compared the effect of IFN-β treatment with the effects associated with evidence of endogenous type I IFN activity on CD4+ T cell and T cell subset activation, monocyte and DC activation and clinical and magnetic resonance imaging disease activity in MS. The gene discussed is IFNB1; the disease is myeloid sarcoma.